| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENO1P |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-388aa |
| 氨基酸序列 | MSILKIHARELFDSRGNPTVEVDLFTSEGLFRAAVPSGASTGIYEVLELQDNDKTRYMGKGVSKPVEPINKTIAPVLVSKKLNVTEQEKIDKLMIEMDGTENKSKFGANAILGVSLAACKASAVEKGVPLYHHIADLSGNSKVILPVPVFNVINGSSHAVTKLAMQEFMVLPVGAANFREAMPIGAEVYHSLKNVIKEKYGKDATGVGDGGAFAPNILENKEGLELLKTAIGKAGYTDKVIVSMDVEASEFFRSGKYDLEFKFLDDPTRYISPDCLADLYKSFIKNYPVVSTEDPFDQDDWGAWQKFTASAGIQVVEDDLRVTNPKRTASAVNEKKCNCLLLKVNQIRSVTESLQACKLAQANGWCVMVPHHSGETENTFITDLVVGL |
| 分子量 | 68.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ENO1蛋白(可能与“ENO1P”相关，或涉及其功能研究)的参考文献示例，结合现有研究整理如下：
---
1. **标题**: *"Autoantibodies to human α-enolase in systemic lupus erythematosus"*
**作者**: Pratesi F. et al.
**摘要**: 研究通过重组人α-烯醇酶(ENO1)检测系统性红斑狼疮(SLE)患者血清中的自身抗体，发现ENO1的磷酸化修饰可能是触发自身免疫反应的关键因素，提示其作为SLE潜在生物标志物的可能性。
2. **标题**: *"Recombinant human α-enolase promotes cell migration and invasion in colorectal cancer models"*
**作者**: Huang J. et al.
**摘要**: 在大肠杆菌中高效表达并纯化重组人ENO1蛋白，体外实验证实其通过激活ERK信号通路增强结直肠癌细胞的迁移和侵袭能力，为靶向ENO1的抗癌策略提供依据。
3. **标题**: *"Expression, purification, and structural characterization of human α-enolase for crystallographic studies"*
**作者**: Liu K. et al.
**摘要**: 利用昆虫细胞表达系统制备高纯度重组人ENO1蛋白，通过X射线晶体学解析其三维结构，揭示其酶活性位点及与底物结合的分子机制。
4. **标题**: *"Phosphorylated α-enolase induces autoantibody response in rheumatoid arthritis"*
**作者**: Cappello P. et al.
**摘要**: 研究发现重组表达的磷酸化ENO1蛋白在类风湿性关节炎(RA)患者中引发显著的抗体反应，提示其修饰后可能参与疾病发生发展。
---
**说明**: “ENO1P”可能指特定修饰(如磷酸化)或亚型的ENO1蛋白，但文献中通常以“phosphorylated ENO1”或直接以“ENO1”表述。上述文献聚焦重组ENO1的表达、功能及临床应用，可能与“ENO1P”研究目标相关。建议进一步结合具体研究背景核实术语定义。
Recombinant human ENO1P protein is derived from the pseudogene ENO1P, which shares high sequence homology with the enolase 1 (ENO1) gene but lacks enzymatic activity due to evolutionary mutations. ENO1. a key glycolytic enzyme, also exhibits "moonlighting" functions in processes like cell migration, hypoxia response, and immune regulation. While ENO1P's pseudogene status initially suggested non-functionality, emerging evidence indicates its transcriptional activity and potential role in regulating ENO1 expression through competitive endogenous RNA (ceRNA) mechanisms, particularly in pathological contexts such as cancer.
The recombinant ENO1P protein is typically produced using bacterial or mammalian expression systems, enabling studies of its structural and functional interactions. It has gained attention as a biomarker and therapeutic target due to its aberrant expression in cancers (e.g., lung, breast) and autoimmune diseases. Researchers utilize it to investigate cross-reactive autoantibodies in paraneoplastic disorders, infectious pathogen interactions (e.g., *Streptococcus*), and tumor microenvironment modulation. Its application extends to developing diagnostic tools and immunotherapies, leveraging molecular mimicry between microbial enolases and human ENO1/ENO1P. Current research focuses on deciphering its non-enzymatic roles in gene regulation and intercellular communication, highlighting its translational potential in precision medicine.
×
